This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma - p. 1147 9. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? - p. 1163 10. Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently? - p. 1179 11. Management of Relapsed Diffuse Large B-cell Lymphoma - p. 1195 12. Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma - p. 1215 13. Promising Novel Agents for Aggressive B-Cell Lymphoma - p. 1229 14. The Spectrum of Double Hit Lymphomas - p. 1239 15. Gray Zone Lymphoma: Current Diagnosis and Treatment Options - p. 1251 16. Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma - p. 1261 17. Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When? - p. 1277 18. The Challenge of Primary Central Nervous System Lymphoma - p. 1293 19. Transformed Lymphoma - p. 1317 20. Update on Burkitt Lymphoma - p. 1333 21. Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm? - p. 1345 22. Index - p. 1371
No hay muestra disponible
No hay ficha técnica disponible
This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma - p. 1147 9. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? - p. 1163 10. Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently? - p. 1179 11. Management of Relapsed Diffuse Large B-cell Lymphoma - p. 1195 12. Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma - p. 1215 13. Promising Novel Agents for Aggressive B-Cell Lymphoma - p. 1229 14. The Spectrum of Double Hit Lymphomas - p. 1239 15. Gray Zone Lymphoma: Current Diagnosis and Treatment Options - p. 1251 16. Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma - p. 1261 17. Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When? - p. 1277 18. The Challenge of Primary Central Nervous System Lymphoma - p. 1293 19. Transformed Lymphoma - p. 1317 20. Update on Burkitt Lymphoma - p. 1333 21. Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm? - p. 1345 22. Index - p. 1371
No hay muestra disponible
No hay ficha técnica disponible
